| scholarly article | Q13442814 |
| P356 | DOI | 10.1185/030079902125000282 |
| P698 | PubMed publication ID | 12017209 |
| P2093 | author name string | Ricardo Castro | |
| Jennifer Ng | |||
| Kerstin Malmstrom | |||
| Gyula Poor | |||
| Albert T Leung | |||
| Matilde Sanchez | |||
| Andre Beaulieu | |||
| Brian Sarembock | |||
| Alberto E Gallacher | |||
| Lisa M Detora | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| placebo | Q269829 | ||
| P304 | page(s) | 49-58 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Current Medical Research and Opinion | Q5195063 |
| P1476 | title | Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial | |
| P478 | volume | 18 |
| Q24615651 | A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity |
| Q34582722 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison |
| Q44484802 | Characterization of etoricoxib, a novel, selective COX-2 inhibitor |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34570225 | Clinical pharmacology of etoricoxib |
| Q34530950 | Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q36861909 | Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments |
| Q44255896 | Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration |
| Q36486905 | Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs |
| Q90374509 | Defining acute flares in knee osteoarthritis: a systematic review |
| Q35925230 | Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis |
| Q44971339 | Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. |
| Q35671108 | Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis |
| Q39320502 | Efficacy and safety of etoricoxib in the treatment of osteoarthritis |
| Q44762080 | Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial |
| Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
| Q41963113 | Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison |
| Q26798013 | Efficacy of physical therapy for the treatment of lateral epicondylitis: a meta-analysis |
| Q35094653 | Emerging trends in the pharmacotherapy of chronic pain |
| Q35016968 | Etoricoxib |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q47756560 | Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly |
| Q39379167 | Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study |
| Q33213983 | Etoricoxib: a highly selective COX-2 inhibitor |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q46188985 | Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. |
| Q35954438 | Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis |
| Q48269682 | Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis |
| Q38962092 | Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis? |
| Q57221140 | Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib |
| Q57169425 | Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity |
| Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
| Q33214797 | Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients |
| Q35093046 | Pharmacotherapy for regional musculoskeletal pain |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
| Q35875744 | Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib |
| Q40976343 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal |
| Q35680546 | Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials |
| Q33566361 | Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice |
| Q37052864 | Risk management profile of etoricoxib: an example of personalized medicine |
| Q64245285 | Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis |
| Q33556721 | The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis |
| Q35028375 | The second generation of COX-2 inhibitors: what advantages do the newest offer? |
Search more.